Breaking News

Curium Pharma Acquires Monrol

Enhances its scale, capabilities and reach across several critical areas, such as Lu-177.

Author Image

By: Charlie Sternberg

Associate Editor

Curium Pharma, a developer, manufacturer, and distributor of nuclear medicine, has acquired Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a nuclear medicine player headquartered in Istanbul, Turkey. The acquisition enhances Curium’s manufacturing capacity of Lutetium-177 (Lu-177) to meet the growing demand for isotope around the world and secure the supply for the future launch of Curium’s Lu-177 drug candidates for Prostate Cancer (currently in development) and Neuroendocrine Tumours (pen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters